T&TvaX

T&TvaX is an Italian biotechnology company focused on the development of next-generation genetic vaccines for cancer immunotherapy. A spin-off from the University of Naples Federico II and CEINGE Biotecnologie Avanzate, the company utilizes a proprietary Greatly Adenoviral (GAd) vector platform to trigger robust T-cell responses against cancer cells. Its primary research focuses on targeting tumor-associated antigens and neoantigens to treat various solid tumors, including non-small cell lung cancer. By leveraging advanced viral vector engineering, T&TvaX aims to provide effective, long-lasting immune-mediated therapeutic solutions for oncology patients. The company's leadership includes veterans of the viral vector field who were instrumental in the development of platforms later acquired by major pharmaceutical firms.